

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/538,452	06/10/2005	Judith McInally	06275-455US1 100927-1P US	3793	
	26164 7590 01/16/2008 FISH & RICHARDSON P.C.			EXAMINER	
P.O BOX 1022			KUDLA, J	KUDLA, JOSEPH S	
MINNEAPOLIS, MN 55440-1022			ART UNIT	PAPER NUMBER	
			1611		
			MAIL DATE	DELIVERY MODE	
			01/16/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/538,452	MCINALLY ET AL.
Office Action Summary	Examiner	Art Unit
	Joseph S. Kudla	1611
The MAILING DATE of this communication a	<u> </u>	ith the correspondence address
Period for Reply	NAME OF TO EXPIRE A M	ONTHYON OR THIRTY (20) DAVO
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory peri - Failure to reply within the set or extended period for reply will, by sta Any reply received by the Office later than three months after the ma earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNIC 1.136(a). In no event, however, may a root will apply and will expire SIX (6) MON tute, cause the application to become AB	CATION. reply be timely filed ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 10) June 2005.	
2a) ☐ This action is FINAL . 2b) ☑ T	his action is non-final.	
3) Since this application is in condition for allow		-
closed in accordance with the practice unde	er <i>Ex par</i> te Quayle, 1935 C.D	0. 11, 453 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) <u>1-7 and 9-20</u> is/are pending in the	application.	
4a) Of the above claim(s) is/are withd	Irawn from consideration.	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1-7 and 9-20</u> are subject to restrict	ion and/or election requireme	ent.
Application Papers		
9) The specification is objected to by the Exam	iner.	
10)☐ The drawing(s) filed on is/are: a)☐ a	ccepted or b) objected to	by the Examiner.
Applicant may not request that any objection to t	* · ·	
Replacement drawing sheet(s) including the corr		
11)☐ The oath or declaration is objected to by the	Examiner. Note the attached	d Office Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for forei a) All b) Some * c) None of:	ign priority under 35 U.S.C. §	§ 119(a)-(d) or (f).
1. ☐ Certified copies of the priority docume	ents have been received	
2. Certified copies of the priority docume		opplication No.
3. ☐ Copies of the certified copies of the p		
application from the International Bure	<u>-</u>	· ·
* See the attached detailed Office action for a l	ist of the certified copies not	received.
·		
Attachment(s)		
1) Notice of References Cited (PTO-892)	4) Interview S	Summary (PTO-413)
2) DNotice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s	s)/Mail Date nformal Patent Application
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	6) Other:	

10/538,452 Art Unit: 1611

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 10 and 13, drawn to a method of inhibiting cysteine protease in a mammal comprising administering a pharmaceutical composition.

Group II, claim(s) 11 and 14, drawn to a method of treating pain in a mammal comprising administering a pharmaceutical composition.

Compound and composition claims 1-7, 9, 12 and 15-20 will be included in the search and examination in whichever group Applicant elects.

2. The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: There is <u>no</u> special technical feature in the instant claim set.

10/538,452 Art Unit: 1611

The technical feature that applicant states in Group I is a method of inhibiting cysteine protease in a mammal comprising administering a compound of claim one. Group II discloses a method of treating pain in a mammal comprising administering a compound of claim one. In the inventions in Groups I and II, the compound functions via different modes of action. For example in Group I, the compound acts as a cysteine protease inhibitor (e.g. blocking the breaking of peptide bonds associated with the amino acid cysteine). Cysteine protease inhibitors are widely known to treat infections by viruses like HIV and Hepatitis C. And for example in Group II, the compound acts to treat pain. Pain is often associated with the stimulation of nociceptors. Because the methods in Group I and II actively operate via separate modes of action and the therapeutic agent is used to elicit a different effect, Groups I and II do not share a common technical feature, therefore; there is no special technical feature and thus the claims lack unity.

Applicant is required to elect a group to be examined on the merits.

Applicant is advised that to be complete, the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

10/538,452 Art Unit: 1611

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103 (a) of the other invention.

Election of Species

Compound

3. If Applicant elects either Group I or II for examination, then a single disclosed specie is required for examination. Claim 1 is generic due to a plurality of the following disclosed patentably distinct species represented in claims 2-7 and 15-20. The compounds depicted in the claims possess different and distinct functionalities. A search is required of each individual species resulting in an unduly extensive search burden. Therefore, Applicant is required to elect a specific compound, to which the elected invention will be examined on the merits. In the event that the elected compound cannot be found, the search and examination will be extended to include additional species. Applicants are required to identify those claims to which the elected compound/invention is drawn.

Applicant is cautioned that the election of a species of compound which has not specifically been disclosed as filed may be determined to be New Matter.

10/538,452 Art Unit: 1611

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

10/538,452 Art Unit: 1611

puph Stadle B

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph S. Kudla whose telephone number is (571) 270-3288. The examiner can normally be reached on 9am-5pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571)-270-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

PHYLLIS SPIVACK PRIMARY EXAMINER

1115 Spivack